Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed colon carcinoma, AJCC/UICC Stage III (Dukes stage C)
Complete tumor resection; Patients operated with curative intent and with no macroscopic or microscopic evidence for remaining tumor who can be randomized to either treatment arm within 8 weeks after surgery. As this is an adjuvant trial patients should never have had any evidence of metastatic disease (including presence of tumor cells in the ascites).
Have a life expectancy of at least 5 years
You may not be if
Pregnant or lactating women
Sexually active males and females (of childbearing potential) unwilling to practice contraception during the study
Previous cytotoxic chemotherapy, radiotherapy or immunotherapy, for the currently treated colon cancer
Patients who have not completely recovered from surgery
Clareo Health | A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
